Calidi Biotherapeutics Inc (CLDI)

Überblick Nachrichten Preisverlauf Forum Prognose

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - Weekly Voice

Tumor-targeting virotherapy from Calidi to appear at 2026 ASCO - Stock Titan

Calidi Biotherapeutics Q4 2025 Earnings: Narrowed Loss Per Share Exceeds Expectations Despite Stock Decline - Newser

Calidi Biotherapeutics Provides Required NYSE American Disclosure - The Manila Times

Calidi Biotherapeutics discloses NYSE-required audit note on going concern status in 2025 financial report. - Pluang

Calidi Biotherapeutics, Inc. Issues Financial Statement Audit Report Highlighting Going Concern Assumption - Quiver Quantitative

Biotech Calidi’s 2025 audit report includes 'going concern' note - Stock Titan

Armistice Capital (CLDI) reports 1.11M shares, 9.99% ownership - Stock Titan

Calidi Highlights Q1 Results and RedTail Platform Progress - TipRanks

Calidi Biotherapeutics 1Q 2026: Net loss $4.42M, EPS $(0.43) — 10-Q Summary - TradingView

Calidi Biotherapeutics (CLDI) Q1 2026 loss, cash runway and warrant overhang detailed - Stock Titan

Calidi Biotherapeutics (NYSE: CLDI) Q1 2026 loss narrows as cash rises - Stock Titan

Biotech Calidi cuts costs, taps AI partner for CLD-401 IND - Stock Titan

Press Release: Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - Moomoo

Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston - GlobeNewswire

TradingKey - TradingKey

How Calidi (CLDI) maintains its competitive edge | Q4 2025: Better Than ExpectedFree Cash Margin - Newser

Calidi Biotherapeutics, Inc. Files Form 8-K for Material Definitive Agreement and Common Stock Purchase Warrants – SEC Filing May 6, 2026 - Minichart

Calidi Biotherapeutics Issues Private Placement Warrant Financing - TipRanks

Calidi Biotherapeutics Issues Warrant for 17.4M Shares, Linked to Up to $4M Stock Buys at $0.23 - TradingView

Calidi Biotherapeutics (CLDI) grants 17.4M-share warrant linked to $4M equity - Stock Titan

Calidi Biotherapeutics announces underwritten public offering - Investing.com

CLDI Stock Price, Quote & Chart | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill

DEFA14A: Others - Moomoo

Calidi Biotherapeutics (CLDI) sets vote on reverse split and larger equity plan - Stock Titan

Calidi Biotherapeutics announces strategic partnership with Transferai - marketscreener.com

Calidi partners with TransferAI for CLD-401 regulatory filing By Investing.com - Investing.com South Africa

Calidi partners with TransferAI for CLD-401 regulatory filing - Investing.com

Calidi Biotherapeutics Announces Strategic Partnership With Transferai - TradingView

Calidi turns to AI software as it pushes CLD-401 toward filing - Stock Titan

Calidi (CLDI) Stock: Breakout Potential Analysis | Q4 2025: Better Than ExpectedVerified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai

CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Revenue Diversification - Cổng thông tin điện tử tỉnh Lào Cai

Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - marketscreener.com

Calidi says CLD-401 drove tumor immune response ahead of 2026 IND - Stock Titan

Calidi presents cancer therapy data at AACR meeting By Investing.com - Investing.com India

Certain Stock Options of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026. - marketscreener.com

Calidi (CLDI) Stock Futures Trade (Trend Weakens) 2026-04-20Price Target - Cổng thông tin điện tử tỉnh Lào Cai

Calidi presents cancer therapy data at AACR meeting - Investing.com

Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - The Manila Times

Calidi targets a hard cancer marker with tumor-restricted engager - Stock Titan

Calidi Biotherapeutics (CLDI) seeks approval for reverse split, 1.95M-plan increase - Stock Titan

Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - TipRanks

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Sahm

Calidi Biotherapeutics to Showcase Advances in Virotherapy at RedChip's Virtual Investor Conference on April 16, 2026 - Quiver Quantitative

Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor ... - Caledonian Record

Calidi Biotherapeutics Announces Participation in RedChip’s - GlobeNewswire

Ähnlich wie CLDI